MCID: BNG095
MIFTS: 44

Benign Giant Cell Tumor

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Benign Giant Cell Tumor

MalaCards integrated aliases for Benign Giant Cell Tumor:

Name: Benign Giant Cell Tumor 12
Giant Cell Tumors 43
Giant Cell Tumor 15

Classifications:



External Ids:

Disease Ontology 12 DOID:200
MeSH 43 D005870
NCIt 49 C3055
SNOMED-CT 67 115238001 443790001
UMLS 71 C0017525

Summaries for Benign Giant Cell Tumor

MalaCards based summary : Benign Giant Cell Tumor, also known as giant cell tumors, is related to tenosynovial giant cell tumor and malignant giant cell tumor of the tendon sheath. An important gene associated with Benign Giant Cell Tumor is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Antibodies and Immunoglobulins, Intravenous have been mentioned in the context of this disorder. Affiliated tissues include bone, pancreas and lung, and related phenotypes are hematopoietic system and cellular

Related Diseases for Benign Giant Cell Tumor

Diseases in the Benign Giant Cell Tumor family:

Malignant Giant Cell Tumor

Diseases related to Benign Giant Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)
# Related Disease Score Top Affiliating Genes
1 tenosynovial giant cell tumor 34.9 SERPINA3 CSF1 CD68
2 malignant giant cell tumor of the tendon sheath 34.5 PTPRC CSF1 CD68
3 pigmented villonodular synovitis 33.3 VIM TNFSF11 TNFRSF11B SERPINA3 PTPRC MMP9
4 cherubism 32.9 TNFSF11 SERPINA3 CSF1 CALCA
5 bone giant cell tumor 32.4 TNFSF11 TNFRSF11B TNFRSF11A SERPINA3 CTSK CSF1
6 synovitis 31.5 TNFSF11 TNFRSF11B MMP9 CD68
7 chondroblastoma 31.3 TNFSF11 SERPINA3 H2AC18
8 villonodular synovitis 31.3 VIM TNFSF11 MMP9 CSF1 CD68
9 giant cell reparative granuloma 31.0 TNFSF11 TNFRSF11A SERPINA3 CD68 CALCA
10 hyperparathyroidism 30.9 TNFSF11 TNFRSF11B FGF23 CALCA BGLAP
11 fibroma 30.9 VIM SERPINA3 DES CD68
12 mesenchymal cell neoplasm 30.9 SERPINA3 FGF23 CD68
13 aneurysmal bone cysts 30.8 TNFSF11 TNFRSF11A CALCA
14 osteonecrosis 30.8 TNFSF11 TNFRSF11B BGLAP
15 spindle cell sarcoma 30.8 VIM SERPINA3 MUC1 DES
16 fibrosarcoma 30.7 VIM PLAUR MMP9 DES
17 cystadenocarcinoma 30.7 VIM SERPINA3 PTPRC MUC1
18 endosteal hyperostosis, autosomal dominant 30.7 TNFSF11 TNFRSF11B CTSK CSF1
19 osteomyelitis 30.7 TNFSF11 CTSK CALCA
20 chordoma 30.7 VIM SERPINA3 MUC1 DES
21 bone giant cell sarcoma 30.7 TNFSF11 CSF1
22 primary hyperparathyroidism 30.7 TNFSF11 TNFRSF11B FGF23 CALCA BGLAP
23 mucinous cystadenocarcinoma 30.6 VIM SERPINA3 PTPRC MUC1
24 malignant fibrous histiocytoma 30.6 VIM SERPINA3 PTPRC MUC1 DES CD68
25 spindle cell carcinoma 30.6 VIM MUC1 DES
26 malignant inflammatory fibrous histiocytoma 30.5 SERPINA3 CD68
27 osteoarthritis 30.5 TNFSF11 TNFRSF11B MMP9 BGLAP
28 osteomalacia 30.5 TNFSF11 FGF23 CALCA BGLAP
29 secretory meningioma 30.5 VIM SERPINA3 MUC1
30 osteitis fibrosa 30.4 FGF23 CALCA BGLAP
31 epulis 30.4 VIM SERPINA3 DES CD68
32 leiomyosarcoma 30.4 VIM SERPINA3 PTPRC MUC1 DES
33 histiocytosis 30.4 TNFSF11 TNFRSF8 SERPINA3 PTPRC
34 carcinosarcoma 30.4 VIM MUC1 DES
35 pleomorphic adenoma 30.4 VIM MUC1 DES
36 fibrous dysplasia 30.3 TNFSF11 TNFRSF11B TNFRSF11A FGF23 CALCA BGLAP
37 pleomorphic lipoma 30.3 SERPINA3 CD68
38 langerhans cell histiocytosis 30.3 TNFSF11 PTPRC CSF1 CD68
39 connective tissue benign neoplasm 30.3 SERPINA3 H2AC18 CD68
40 reticulohistiocytic granuloma 30.3 SERPINA3 CD68
41 malignant fibrous histiocytoma of bone 30.2 SERPINA3 DES
42 neurofibroma 30.2 VIM MUC1 MITF
43 pycnodysostosis 30.2 TNFSF11 MITF CTSK
44 angiosarcoma 30.2 VIM MUC1 CD68
45 multicentric carpotarsal osteolysis syndrome 30.1 TNFSF11 TNFRSF11B TNFRSF11A CTSK CSF1 BGLAP
46 pneumothorax 30.1 VIM MUC1 MMP9
47 glomus tumor 30.1 VIM MUC1 DES
48 neurilemmoma 30.0 VIM SERPINA3 MUC1 MITF DES
49 bone inflammation disease 30.0 TNFSF11 TNFRSF11B SERPINA3 MMP9 H2AC18
50 dermatofibrosarcoma protuberans 30.0 VIM SERPINA3 DES

Graphical network of the top 20 diseases related to Benign Giant Cell Tumor:



Diseases related to Benign Giant Cell Tumor

Symptoms & Phenotypes for Benign Giant Cell Tumor

MGI Mouse Phenotypes related to Benign Giant Cell Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 BGLAP CD68 CSF1 CTSK FGF23 MITF
2 cellular MP:0005384 10.17 BGLAP CSF1 CTSK DES MITF MMP9
3 homeostasis/metabolism MP:0005376 10.13 BGLAP CSF1 CTSK DES FGF23 MITF
4 immune system MP:0005387 10.1 BGLAP CD68 CSF1 CTSK FGF23 MITF
5 endocrine/exocrine gland MP:0005379 10.06 BGLAP CSF1 CTSK FGF23 MITF PTPRC
6 limbs/digits/tail MP:0005371 9.76 CSF1 CTSK FGF23 MITF MMP9 TNFRSF11A
7 respiratory system MP:0005388 9.61 CSF1 CTSK FGF23 MMP9 PLAUR PTPRC
8 skeleton MP:0005390 9.36 BGLAP CD68 CSF1 CTSK FGF23 MITF

Drugs & Therapeutics for Benign Giant Cell Tumor

Drugs for Benign Giant Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4
2 Immunoglobulins, Intravenous Phase 4
3 Antibodies, Monoclonal Phase 4
4 Immunoglobulin G Phase 4
5 Immunoglobulins Phase 4
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Phenol Approved, Experimental Phase 3 108-95-2 996
8
Ethanol Approved Phase 3 64-17-5 702
9
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Anesthetics, General Phase 3
12 Anesthetics, Intravenous Phase 3
13 Cola Phase 3
14 Liver Extracts Phase 3
15 Narcotics Phase 3
16 Analgesics, Opioid Phase 3
17 Diphosphonates Phase 3
18 Polymethyl Methacrylate Phase 3
19
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
20
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
21
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
22
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
23
Ipilimumab Approved Phase 2 477202-00-9
24
nivolumab Approved Phase 2 946414-94-4
25
Denosumab Approved Phase 2 615258-40-7
26
Zoledronic Acid Approved Phase 2 118072-93-8 68740
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 1406-16-2
28 Protein Kinase Inhibitors Phase 2
29 Grapefruit Seed Extract Phase 2
30 Anti-HIV Agents Phase 2
31 Anti-Infective Agents Phase 2
32 Antiviral Agents Phase 2
33 Interleukin-2 Phase 2
34 Analgesics, Non-Narcotic Phase 2
35 Anti-Retroviral Agents Phase 2
36 Antimetabolites Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38 Trace Elements Phase 1, Phase 2
39 Micronutrients Phase 1, Phase 2
40 Vitamins Phase 1, Phase 2
41 Hormones Phase 1, Phase 2
42 Nutrients Phase 1, Phase 2
43 Calcium, Dietary Phase 1, Phase 2
44 Calciferol Phase 1, Phase 2
45 Pharmaceutical Solutions Phase 1, Phase 2
46
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
47
Calcium Nutraceutical Phase 1, Phase 2 7440-70-2 271
48
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
49
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
50
Tolbutamide Approved, Investigational Phase 1 64-77-7 5505

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
2 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
3 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
6 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Active, not recruiting NCT02371369 Phase 3 Pexidartinib;Placebo
7 An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone Completed NCT00396279 Phase 2
8 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone Completed NCT00680992 Phase 2 Denosumab
9 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo
10 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
11 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
12 Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts Completed NCT03415477 Phase 1, Phase 2 Denosumab (Xgeva)
13 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
14 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Recruiting NCT03069469 Phase 1, Phase 2 DCC-3014
15 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
16 A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES Recruiting NCT02554812 Phase 2 Avelumab;Utomilumab;PF-04518600;PD 0360324;CMP-001
17 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
18 A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT) Active, not recruiting NCT02471716 Phase 1, Phase 2
19 A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Active, not recruiting NCT01207492 Phase 2 nilotinib
20 An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia Enrolling by invitation NCT03571191 Phase 2 Denosumab
21 A Phase Ib/II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of JMT103 in Surgically Unsalvageable or Refractory Giant Cell Tumor of Bone Not yet recruiting NCT04255576 Phase 1, Phase 2
22 Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study Terminated NCT00889590 Phase 2 Zoledronic acid
23 Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Terminated NCT01564121 Phase 1, Phase 2 acid Zoledronic
24 Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors Completed NCT01494688 Phase 1 Paclitaxel;RO5509554
25 An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients Active, not recruiting NCT03291288 Phase 1 Tolbutamide;Midazolam;Pexidartinib
26 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT) Terminated NCT02673736 Phase 1 PLX73086
27 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors Terminated NCT01804530 Phase 1 PLX7486 TsOH
28 Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses Unknown status NCT03171857
29 Il Tumore a Cellule Giganti Delle estermità Completed NCT02996734
30 An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects Recruiting NCT04223635 Early Phase 1 Pexidartinib
31 Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series Active, not recruiting NCT04002817
32 A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS) Active, not recruiting NCT02948088
33 Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China:Correlation Between Recurrence and Drug Withdrawl Not yet recruiting NCT03358212 Denosumab
34 MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases Not yet recruiting NCT03106675
35 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide

Search NIH Clinical Center for Benign Giant Cell Tumor

Cochrane evidence based reviews: giant cell tumors

Genetic Tests for Benign Giant Cell Tumor

Anatomical Context for Benign Giant Cell Tumor

MalaCards organs/tissues related to Benign Giant Cell Tumor:

40
Bone, Pancreas, Lung, Liver, Monocytes, Thyroid, Breast

Publications for Benign Giant Cell Tumor

Articles related to Benign Giant Cell Tumor:

(show top 50) (show all 1746)
# Title Authors PMID Year
1
RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. 61 54
16939392 2006
2
[Expression of macrophage inflammatory protein-1alpha, a disintegrin-like and metalloproteinase 8 and 12, and CD68 protein in giant cell lesions of jaw and giant cell tumors of long bone]. 54 61
16251041 2005
3
Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. 54 61
16325507 2005
4
Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions. 54 61
15205688 2004
5
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. 61 54
12970268 2003
6
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 54 61
11863217 2002
7
Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. 61 54
12865629 2002
8
[Expression of ADAM12 (Meltrin-alpha) gene in giant cell tumor of bone]. 61 54
11769731 2001
9
Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. 61 54
11336917 2001
10
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. 54 61
10574572 1999
11
Soft tissue giant cell tumor of low malignant potential: a proposal for the reclassification of malignant giant cell tumor of soft parts. 54 61
10496598 1999
12
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. 61 54
7495280 1995
13
Osteocalcin expression in primary bone tumors--in situ hybridization and immunohistochemical study. 54 61
8593206 1995
14
Estrogen modulation of osteoclast lysosomal enzyme secretion. 61 54
7759564 1995
15
Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. 54 61
7962073 1994
16
Expression of Ki-1 antigen (CD30) in mesenchymal tumors. 61 54
2169996 1990
17
Integration of denosumab therapy in the management of giant cell tumors of bone. 61
32280167 2020
18
The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex. 61
32409220 2020
19
Successful percutaneous treatment of bone tumors using microwave ablation in combination with Zoledronic acid infused PMMA cementoplasty. 61
32265080 2020
20
Bone Tumors: Benign Bone Tumors. 61
32573182 2020
21
CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis. 61
32238382 2020
22
Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. 61
32478598 2020
23
Benign Hand Tumors (Part I): Cartilaginous and Bone Tumors. 61
32506966 2020
24
Giant Cell Tumor of the Ring Finger Distal Phalanx. 61
32527520 2020
25
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of spinal giant cell tumors. 61
32444915 2020
26
Erratum: Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. 61
32433328 2020
27
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. 61
32377818 2020
28
COVID-19 and Management of Orthopedic Emergencies. Producing a Consensus of Experts. 61
32548837 2020
29
Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review. 61
31794487 2020
30
Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? 61
32401001 2020
31
Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone. 61
32478667 2020
32
Optimal treatment for tenosynovial giant cell tumors of the hand. 61
32350187 2020
33
Functions of Exogenous RUNX2 in Giant Cell Tumor of Bone In Vitro. 61
32154660 2020
34
FOS-ANKH and FOS-RUNX2 Fusion Genes in Osteoblastoma. 61
32108038 2020
35
[Giant cell tumor of bone : Morphology, molecular pathogenesis, and differential diagnosis]. 61
32086536 2020
36
[Molecular pathology in the diagnosis of bone tumors: current concepts]. 61
31993697 2020
37
Giant cell tumor of soft tissue of the nasopharynx: A case report. 61
32179497 2020
38
Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. 61
31784095 2020
39
[Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value]. 61
32074722 2020
40
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. 61
31862477 2020
41
Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors. 61
31469468 2020
42
Benign Pediatric Jaw Lesions at Massachusetts General Hospital Over 13 Years. 61
32114009 2020
43
The functional outcomes and complications of different reconstruction methods for Giant cell tumor of the distal radius: comparison of Osteoarticular allograft and three-dimensional-printed prosthesis. 61
32013950 2020
44
Surgical strategies for primary malignant tumors of the thoracic and lumbar spine. 61
31843511 2020
45
Can Denosumab cure giant cell tumors of the spine? A case report and literature review. 61
31529151 2020
46
Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology. 61
31651524 2020
47
Image-Guided Percutaneous Management of Skull and Spine Giant Cell Tumors: Case Report of 2 Challenging Cases Successfully Treated with Doxycycline Sclerotherapy. 61
31660538 2020
48
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. 61
32440095 2020
49
Oncology and functional prognosis are both vital in the surgical treatment of RGCTs around the knee joint. 61
32269741 2020
50
Radical Resection of a Recurrent Giant Cell Tumor of the Distal Ulna and Immediate Reconstruction With a Distal Radio-Ulnar Joint Implant Arthroplasty. 61
31965863 2020

Variations for Benign Giant Cell Tumor

Expression for Benign Giant Cell Tumor

Search GEO for disease gene expression data for Benign Giant Cell Tumor.

Pathways for Benign Giant Cell Tumor

Pathways related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 VIM TNFSF11 TNFRSF8 TNFRSF11B TNFRSF11A SERPINA3
2
Show member pathways
13.17 VIM TNFSF11 TNFRSF8 TNFRSF11B TNFRSF11A MUC1
3
Show member pathways
12.9 TNFSF11 TNFRSF11B TNFRSF11A PTPRC MMP9 ADAM12
4
Show member pathways
12.27 TNFSF11 TNFRSF11B TNFRSF11A MITF CTSK
5 11.74 TNFSF11 TNFRSF11B TNFRSF11A MITF CTSK CSF1
6 11.73 TNFSF11 TNFRSF11A CTSK CSF1
7 11.69 PTPRC DES BGLAP
8
Show member pathways
11.65 TNFSF11 TNFRSF8 TNFRSF11B TNFRSF11A
9
Show member pathways
11.55 TNFSF11 TNFRSF8 TNFRSF11A
10 11.34 PLAUR MMP9 FGF23 BGLAP
11 11.2 PLAUR MMP9 BGLAP
12 10.83 VIM TNFSF11 FGF23 DES CSF1
13 10.76 TNFSF11 TNFRSF11B TNFRSF11A CTSK
14 10.67 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP
15 10.4 TNFSF11 TNFRSF11B FGF23 BGLAP

GO Terms for Benign Giant Cell Tumor

Cellular components related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 VIM TNFSF11 TNFRSF8 TNFRSF11B TNFRSF11A PTPRC
2 extracellular space GO:0005615 9.65 TNFSF11 TNFRSF11B SERPINA3 MUC1 MMP9 FGF23
3 extracellular region GO:0005576 9.4 TNFSF11 TNFRSF11B SERPINA3 PLAUR MUC1 MMP9

Biological processes related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.91 SERPINA3 PTPRC PLAUR MMP9 CD68
2 cytokine-mediated signaling pathway GO:0019221 9.77 VIM TNFSF11 MUC1 MMP9 CSF1
3 monocyte chemotaxis GO:0002548 9.63 TNFSF11 TNFRSF11A CALCA
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.62 TNFSF11 TNFRSF8 TNFRSF11B TNFRSF11A
5 response to magnesium ion GO:0032026 9.52 TNFRSF11B FGF23
6 negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:2001268 9.49 PLAUR MMP9
7 positive regulation of homotypic cell-cell adhesion GO:0034112 9.48 TNFSF11 PLAUR
8 TNFSF11-mediated signaling pathway GO:0071847 9.43 TNFSF11 TNFRSF11A
9 osteoclast proliferation GO:0002158 9.4 TNFSF11 CSF1
10 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.26 TNFSF11 TNFRSF11A
11 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.16 TNFSF11 TNFRSF11A
12 regulation of osteoclast differentiation GO:0045670 9.13 TNFSF11 MITF BGLAP
13 osteoclast differentiation GO:0030316 8.92 TNFSF11 TNFRSF11A MITF CSF1

Sources for Benign Giant Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....